Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa

Objectives: In a multicenter, open-label, treatment protocol (HGT-REP-059; NCT01031173), clinical effects and tolerability of agalsidase alfa (agalα; 0.2 mg/kg every other week) were evaluated in patients with Fabry disease who were treatment naïve or switched from agalsidase beta (switch). Over 24...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JIMD Rep
Main Authors: Goker-Alpan, Ozlem, Nedd, Khan, Shankar, Suma P., Lien, Yeong-Hau H., Weinreb, Neal, Wijatyk, Anna, Chang, Peter, Martin, Rick
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4484907/
https://ncbi.nlm.nih.gov/pubmed/25822820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/8904_2015_422
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares